The FDA also required changes to the labels to achieve a more uniform presentation of side effects and risk information for all of the drugs in the GLP-1 category, including adding or changing subsections for Acute Pancreatitis and Severe Gastrointestinal Adverse Reactions and revising the Patient Counseling section and Medication Guide. Some of the labels were also updated with post-marketing reports of hair loss (alopecia) and the neurological symptom of altered sense of touch, or dysethesia
From your first consultation to follow-ups, youll receive ongoing monitoring and adjustments as needed, ensuring safety and maximum results
A federal judge on Wednesday dismissed part of Eli Lilly's lawsuit against the Houston-based Empower Pharmacy - the latest development in the pharmaceutical giant's bid to curb sales of cheaper, less-regulated versions of their blockbuster GLP-1 weight loss drug
CAS Numbers: 137525-51-0, 77591-33-4, 89030-95-5, 67727-97-3
The appointed lawyers will address issues shared across the lawsuits and guide the selection and preparation of representative claims for potential bellwether trials
I see every day how harmful that stigma is, and how it stops people from getting care that could change their health and their lives
